## SEC Form 4

Instruction 1(b).

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden

0.5

hours per response:

| Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 |  |
|--|--|
| or Section 30(h) of the Investment Company Act of 1940                 |  |

| 1. Title of Secur            | ity (Instr. 3)         |              | 2. Transaction<br>Date                  | 2A. Deemed<br>Execution Date,   | 3.<br>Transaction | 4. Securities Acquired (A)<br>Disposed Of (D) (Instr. 3, 4 |   | 5. Amount of<br>Securities                | 6. Ownership<br>Form: Direct | 7. Nature<br>of Indirect |
|------------------------------|------------------------|--------------|---|---------------------------------|-------------------|--|---|---|------------------------------|--------------------------|
|                              |                        | Table I - No | on-Derivative                           | Securities Ac                   | quired, Dis       | sposed of, or Bene   | ficially  | Owned                                     |                              |                          |
| (City)                       | (State)                | (Zip)        |   |                                 |                   |  |   | Form filed by Mo<br>Person                | ore than One Re              | porting                  |
| Street)<br>LONDON X0 SE1 2RE |                        |              |   | Amendment, Date                 | of Original File  | ed (Month/Day/Year)  | 6. Indiv<br>Line)<br>X                              | vidual or Joint/Grou<br>Form filed by Or  | , ox                         |                          |
| (Last)<br>3 MORE LO          | (First)<br>NDON RIVERS | (Middle)     |   | ate of Earliest Tran<br>26/2022 | saction (Mont     | h/Day/Year)  | X   | Officer (give title<br>below)<br>Presiden | Other<br>below<br>at and CEO | (specify<br>)            |
|                              | tress of Reporting     |              | suer Name <b>and</b> Tio<br>cona Pharma |                                 |                   |  | ationship of Reporti<br>all applicable)<br>Director | ng Person(s) to<br>10% (                  |                              |                          |

|                                | (Month/Day/Year) | if any<br>(Month/Day/Year) | Code (<br>8) | Instr. |                          |               |                   | Beneficially<br>Owned Following<br>Reported | (D) or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4) |
|--------------------------------|------------------|----------------------------|--------------|--------|--------------------------|---------------|-------------------|---|-----------------------------------|---------------------------------------|
|                                |                  |                            | Code         | v      | Amount                   | (A) or<br>(D) | Price             | Transaction(s)<br>(Instr. 3 and 4)          |                                   | (111511: 4)                           |
| Ordinary Shares <sup>(1)</sup> | 09/26/2022       |                            | A            |        | 3,600,000 <sup>(2)</sup> | Α             | \$ <mark>0</mark> | 18,863,560 <sup>(3)</sup>                   | D                                 |                                       |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

|   |   |  |   |                              |   |     |     | -  |   |       |   | -  |  |  |  |
|---|---|--|---|------------------------------|---|-----|-----|--|---|-------|---|--|--|--|--|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of  |     | 6. Date Exerc<br>Expiration Da<br>(Month/Day/Y | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr.<br>3 and 4) |       | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|   |   |  |   | Code                         | v | (A) | (D) | Date<br>Exercisable                            | Expiration<br>Date  | Title | Amount<br>or<br>Number<br>of<br>Shares              |  |  |  |  |

Explanation of Responses:

1. Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

2. Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 900,000 RSUs vesting on November 1, 2023 and the balance vesting in 12 equal quarterly installments thereafter.

3. Consists of (i) 10,702,720 Ordinary Shares underlying RSUs (which are represented by 1,337,840 ADSs); and (ii) 8,160,840 Ordinary Shares underlying 1,020,105 ADSs.

/s/ Claire Poll, Attorney-in-09/28/2022 fact for David Zaccardelli Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See